Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.0K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.8K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of monotonically classifying pairs of genes for ordinal disease outcomes.

Bioinformatics advances·2026
Same author

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression.

Molecular oncology·2026
Same author

Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes.

Cancer discovery·2026
Same author

Ex Vivo Immuno-Oncology Platform Reveals Spatial T-cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer.

Cancer immunology research·2026
Same author

Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia.

Cancer research·2025
Same author

Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer.

Cancer research·2025

Related Experiment Video

Updated: Sep 13, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer.

Giulia Micoli1, Kari Lavikka1, Yilin Li1

  • 1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Cancer Discovery
|July 30, 2025
PubMed
Summary

This study identifies five ovarian high-grade serous carcinoma (HGSC) subtypes based on genomic instability. Three subtypes, lacking homologous recombination deficiency (HRD), show potential for targeted CHK1 inhibition with prexasertib.

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

Related Experiment Videos

Last Updated: Sep 13, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

Area of Science:

  • Genomics
  • Oncology
  • Cancer Biology

Background:

  • Ovarian high-grade serous carcinoma (HGSC) exhibits significant genomic instability and heterogeneity.
  • Homologous recombination deficiency (HRD) predicts response to PARP inhibitors and platinum chemotherapy, but HR-proficient (HRP) tumors respond poorly.
  • Current therapies are limited for HRP HGSC patients due to treatment resistance.

Purpose of the Study:

  • To overcome HGSC heterogeneity by characterizing its genomic landscape.
  • To identify distinct HGSC subtypes based on chromosomal instability (CIN) signatures.
  • To discover novel therapeutic targets for currently untreatable HRP HGSC subtypes.

Main Methods:

  • Whole-genome sequencing of 640 tumors from 243 HGSC patients.
  • Chromosomal instability (CIN) signature-based analysis of structural variations.
  • Validation of identified subtypes in an independent patient cohort.
  • Organoid experiments to assess drug sensitivity.

Main Results:

  • Five distinct HGSC subtypes were identified and validated, based on CIN signatures.
  • Two HRD subtypes showed favorable responses to existing therapies.
  • Three HRP subtypes displayed unique genomic alterations, gene expression, and tumor microenvironment profiles.
  • Organoid models demonstrated subtype-specific sensitivity to CHK1 inhibition.

Conclusions:

  • Genomic characterization reveals novel HGSC subtypes with distinct clinical implications.
  • Targeted CHK1 inhibition with prexasertib shows promise for treating HRP HGSC patients.
  • This research offers a framework for personalized treatment strategies in HGSC.